Business Context and Reporting Period
This Form 8-K was filed by Cerulean Pharma Inc. on May 5, 2017. The filing addresses a regulatory notice regarding the company's stock listing status on the Nasdaq Global Market. Note: The metadata provided in the request lists "Dare Bioscience, Inc.", but the filing text explicitly identifies the registrant as "Cerulean Pharma Inc."
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on stock price compliance rather than financial performance metrics.
Material Changes
The primary material event is the receipt of a deficiency letter from the Nasdaq Listing Qualifications Department. The company's common stock bid price closed below the minimum $1.00 per share requirement for 30 consecutive business days, violating Nasdaq Listing Rule 5450(a)(1).
Outlook, Risks, and Management Commentary
- Compliance Period: The company has been granted an initial 180-day compliance period, ending November 1, 2017, to regain compliance.
- Compliance Requirement: To cure the deficiency, the stock must close at $1.00 or more for 10 consecutive business days before the compliance date.
- Delisting Risk: If compliance is not met by the deadline, the company may be delisted unless it qualifies for an additional 180-day period by transferring to the Nasdaq Capital Market.
- Management Action: Management intends to monitor the stock price and may consider a reverse stock split to regain compliance, though there is no assurance of success.
- Appeal Process: If delisted, the company may appeal the decision to a NASDAQ Listing Qualifications Panel, with the stock expected to remain listed pending the decision.
Investor Verification Checklist
- Verify the current closing bid price of Cerulean Pharma Inc. stock to assess proximity to the $1.00 threshold.
- Monitor for any announcements regarding a reverse stock split or other capital structure changes.
- Check for updates on the company's ability to meet the 10-day consecutive closing requirement before November 1, 2017.
- Review the company's eligibility for transfer to the Nasdaq Capital Market if the initial compliance period expires.